Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00411619

Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex

Everolimus (RAD001)Therapy of Giant Cell Astrocytomas in Patients With Tuberous Sclerosis Complex

Sponsor: Children's Hospital Medical Center, Cincinnati

Conditions Subependymal Giant Cell Astrocytoma Tuberous Sclerosis

Interventions Everolimus

Updated 8 times since 2017 Last updated: Oct 17, 2014 Started: Jan 31, 2007 Primary completion: Jan 31, 2014 Completion: Jan 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Subependymal Giant Cell Astrocytoma and Tuberous Sclerosis, this trial is completed. The trial is conducted by Children's Hospital Medical Center, Cincinnati and has accumulated 8 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1_PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Children's Hospital Medical Center, Cincinnati
Novartis

Data source: Children's Hospital Medical Center, Cincinnati

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cincinnati, United States